当前位置:
首页
网刊
解决药物可及性的组合策略初探
解决药物可及性的组合策略初探
耿文军1,2,吴 斌3,邓声菊3,苗艳妮4,丁锦希1

1 中国药科大学,南京 211198;2 正大天晴药业集团股份有限公司,南京 210023;3 北京国知专利 预警咨询有限公司,北京 100081;4 国家知识产权局专利局医药生物发明审查部,北京 100088
A preliminary study of combination strategy on solving the  problem of drug accessibility
(1 China Pharmaceutical University, Nanjing 211198, China; 2 Chia Tai Tianqing Pharmaceutical Group  Co., Ltd., Nanjing 210023, China; 3 Beijing Guozhi Patent Warning Consulting Co., Ltd.,  Beijing 100081, China; 4 Ministry of Medical and Biological Invention of the State Intellectual  Property Office of the P.R.C, Beijing 100088, China)

摘要参考文献相关文章

起始页:2502

摘要:[摘要] 本文从专利保护、刑事司法、注册审批与医疗保险等制度分析入手,辩证解析药物可及性的解决途径;再从利益平衡的角度,探析药品产业化不同阶段渐进性解决药物可及性的组合策略。

关键词:[关键词] 药物可及性;专利;刑事司法;注册审批;医疗保险

通讯作者:

基金项目:

作者简介:

Abstract:[Abstract] This paper discussed from the patent protection, criminal justice, registration approval and medical insurance system analysis, and dialectically analyzeded the problem of drug accessibility and its solutions. From the perspective of interest balance, this paper also proposed the combination strategy to solve the problem of drug accessibility for different stages of pharmaceutical industry.

Key words:[Key words] drug accessibility; patent; criminal justice; registration approval; medical insurance

    [1] 古村.药品可及性问题分析[J].科技创新与知识产权,2011, 3(17):74-76.
    [2] World Health Organization. Department of Essential Drugs and Medicines Policy. WHO medicines strategy: framework for action in Essential Drugs and Medicines Policy 2000-2003[R]. World Health Organization, 2000:31-33.
    [3] 张清奎.医药及生物技术领域知识产权战略实务[M]. 北京:知识产权出版社,2008: 38-39.
    [5] 褚淑贞, 唐卉. 药物可及性框架内的制药企业社会责任探析[J].企业导报, 2013,14(6):235-237.
    [6] 湖南省沅江市人民检察院.关于对陆勇妨害信用卡管理和销售极爱要案决定不起诉的释法说理书[EB/OL]. (2015-02-26)[2017-08-08]. http://www.ajxxgk.jcy.gov.cn/html/20150226/2/356737.html.
    [7] 新药汇. 2014年中国医药行业化学药1.1类新药及3.1类新药现状全面分析报告[EB/OL]. (2015-01-16)[2017-02-20].http://xiaoyaohui.com/news/2015/16/4877.html.
    [8] 国家卫生计生委. 关于做好国家谈判药品集中采购的通知(国卫药政发(2016)19号)[EB/OL].(2016-05-20)[2017-08-08].http://www.nhfpc.gov.cn/yaozs/s3577/201605/15fb 339b6b854b8981dee3306d76ce27.shtml.
    [9] RAVIKANT BHARDWAJ, RAJU KD, PADAMAVATIETC M. The impact of patent linkage on marketing of generic drugs[J]. JIPR,2013,18(7):316-322.